Ivosidenib works by inhibiting the mutant IDH1 enzyme, which is responsible for the production of the oncometabolite D-2-hydroxyglutarate (2-HG). Elevated levels of 2-HG are associated with aberrant cell differentiation and proliferation in cancer. By inhibiting IDH1, ivosidenib reduces 2-HG levels, thereby promoting the differentiation of malignant cells into more mature forms, which can lead to a reduction in tumor burden.
